Subtype
Adrenal Gland Neoplasm
CI-CAN-00000413Explore in graph →
Non-malignant54 active trials1 approved drugs4 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000413Explore in graph →
Clinical trials
262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03649438 | 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma | no longer available | — | — | University of Texas Southwestern Medical CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT01838187 | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | no longer available | — | — | Children's Hospital Medical Center, CincinnatiOTHER |
| 1 |
| Aug 18, 2023 |
| clinicaltrials |
| NCT02431715 | 18F-FDOPA PET in Neuroendocrine Tumours | no longer available | — | — | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials